Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
BMS-986406 by Bristol-Myers Squibb for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval
BMS-986406 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According...
BMS-986406 by Bristol-Myers Squibb for Recurrent Head And Neck Squamous Cell Carcinoma: Likelihood of Approval
BMS-986406 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Recurrent Head And Neck Squamous Cell...
BMS-986406 by Bristol-Myers Squibb for Metastatic Renal Cell Carcinoma: Likelihood of Approval
BMS-986406 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Metastatic Renal Cell Carcinoma. According to...
BMS-986406 by Bristol-Myers Squibb for Metastatic Ovarian Cancer: Likelihood of Approval
BMS-986406 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Metastatic Ovarian Cancer. According to GlobalData,...
BMS-986406 by Bristol-Myers Squibb for Gastroesophageal (GE) Junction Carcinomas: Likelihood of Approval
BMS-986406 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Gastroesophageal (GE) Junction Carcinomas. According to...
BMS-986406 by Bristol-Myers Squibb for Non-Small Cell Lung Cancer: Likelihood of Approval
BMS-986406 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Non-Small Cell Lung Cancer. According to...
BMS-986406 by Bristol-Myers Squibb for Solid Tumor: Likelihood of Approval
BMS-986406 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Solid Tumor. According to GlobalData, Phase...
BMS-986406 by Bristol-Myers Squibb for Bladder Cancer: Likelihood of Approval
BMS-986406 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Bladder Cancer. According to GlobalData, Phase...
BMS-986406 by Bristol-Myers Squibb for Gastric Cancer: Likelihood of Approval
BMS-986406 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Gastric Cancer. According to GlobalData, Phase...
BMS-986406 by Bristol-Myers Squibb for Squamous Non-Small Cell Lung Cancer: Likelihood of Approval
BMS-986406 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Squamous Non-Small Cell Lung Cancer. According...
BMS-986406 by Bristol-Myers Squibb for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
BMS-986406 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Pancreatic Ductal Adenocarcinoma. According to GlobalData,...
BMS-986406 by Bristol-Myers Squibb for Squamous Non-Small Cell Lung Cancer: Likelihood of Approval
BMS-986406 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Squamous Non-Small Cell Lung Cancer. According...
BMS-986406 by Bristol-Myers Squibb for Soft Tissue Sarcoma: Likelihood of Approval
BMS-986406 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Soft Tissue Sarcoma. According to GlobalData,...
BMS-986406 by Bristol-Myers Squibb for Malignant Mesothelioma: Likelihood of Approval
BMS-986406 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Malignant Mesothelioma. According to GlobalData, Phase...
BMS-986406 by Bristol-Myers Squibb for Metastatic Melanoma: Likelihood of Approval
BMS-986406 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Metastatic Melanoma. According to GlobalData, Phase...
BMS-986406 by Bristol-Myers Squibb for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
BMS-986406 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Pancreatic Ductal Adenocarcinoma. According to GlobalData,...
BMS-986406 by Bristol-Myers Squibb for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
BMS-986406 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Triple-Negative Breast Cancer (TNBC). According to...